Ankura™ TAA Stent Graft System Post-Market Clinical Follow-up Study

NCT05639569

Status	RECRUITING
Sponsor	Lifetech Scientific (Shenzhen) Co., Ltd.
Enrollment	145 participants

Key Eligibility Criteria

Inclusion (14)

- Patient has descending thoracic aortic aneurysm (DTA) or type B aortic dissection (TBAD), who needs endovascular repair (TEVAR).
- Life expectancy \> 1 year.
- Patient or legally authorized representative understands the nature of the clinical trial, agrees to its provisions, agrees to comply with the requirements of the study including a 3-year follow-up, and signed applicable Informed Consent Form.
- Patient's characteristics consistent with Ankura™ Stent Graft System IFU and sizing guidelines, which indicate as following:
- For descending thoracic aortic aneurysm (DTA) patient:

... and 9 more (see full listing online)

Exclusion (24)

- Patient with any contraindications mentioned in the Ankura™ Stent Graft System IFU:
- Patients with acute systemic infection;
- Patients who have had other devices implanted in the cardiovascular cavity, which will interfere with the placement of this device;
- Patients with mesenteric blood flow mainly supplied by the inferior mesenteric artery;
- Patients who have allergic reaction to the device;

... and 19 more (see full listing online)

Locations (8 total)

RHÖN-KLINIKUM Campus Bad Neustadt, Bad Neustadt an der Saale, Germany
Asklepios Klinik Nord Heidberg, Hamburg, Germany
St. Franziskus Hospital Münster, Münster, Germany
... and 5 more locations